Agios Pharmaceuticals (NASDAQ:AGIO) Upgraded by BidaskClub to “Buy”

BidaskClub upgraded shares of Agios Pharmaceuticals (NASDAQ:AGIO) from a hold rating to a buy rating in a research report released on Tuesday, BidAskClub reports.

Several other brokerages also recently weighed in on AGIO. Zacks Investment Research downgraded Agios Pharmaceuticals from a buy rating to a hold rating and set a $56.00 target price for the company. in a research note on Tuesday, June 16th. Piper Sandler raised their target price on Agios Pharmaceuticals from $70.00 to $80.00 and gave the company an overweight rating in a research note on Friday, June 12th. Guggenheim raised their target price on Agios Pharmaceuticals from $60.00 to $66.00 and gave the company a buy rating in a research note on Monday, June 15th. Citigroup lifted their price target on Agios Pharmaceuticals from $64.00 to $75.00 and gave the stock a buy rating in a research note on Monday, June 15th. Finally, Oppenheimer reiterated a hold rating on shares of Agios Pharmaceuticals in a research note on Monday, June 15th. Four analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. Agios Pharmaceuticals has an average rating of Buy and a consensus price target of $68.62.

NASDAQ:AGIO opened at $53.48 on Tuesday. The business’s 50-day moving average is $49.97 and its two-hundred day moving average is $46.51. The company has a debt-to-equity ratio of 0.17, a current ratio of 8.41 and a quick ratio of 8.27. The firm has a market capitalization of $3.56 billion, a PE ratio of -9.11 and a beta of 2.14. Agios Pharmaceuticals has a 12 month low of $27.77 and a 12 month high of $54.68.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its earnings results on Thursday, April 30th. The biopharmaceutical company reported ($0.59) earnings per share for the quarter, beating the consensus estimate of ($1.67) by $1.08. The company had revenue of $87.10 million during the quarter, compared to the consensus estimate of $31.12 million. Agios Pharmaceuticals had a negative return on equity of 63.85% and a negative net margin of 205.20%. The company’s revenue was up 188.4% on a year-over-year basis. During the same period last year, the firm earned ($1.59) earnings per share. Equities analysts anticipate that Agios Pharmaceuticals will post -4.67 EPS for the current year.

In other Agios Pharmaceuticals news, insider Christopher Bowden sold 3,583 shares of Agios Pharmaceuticals stock in a transaction that occurred on Wednesday, May 20th. The stock was sold at an average price of $50.01, for a total value of $179,185.83. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 3.16% of the company’s stock.

A number of hedge funds have recently modified their holdings of AGIO. Pearl River Capital LLC acquired a new position in Agios Pharmaceuticals in the first quarter valued at approximately $32,000. Carroll Financial Associates Inc. bought a new stake in shares of Agios Pharmaceuticals during the first quarter valued at approximately $48,000. Advisor Group Inc. raised its holdings in shares of Agios Pharmaceuticals by 551.3% during the fourth quarter. Advisor Group Inc. now owns 1,244 shares of the biopharmaceutical company’s stock valued at $59,000 after buying an additional 1,053 shares during the last quarter. ETF Managers Group LLC raised its holdings in shares of Agios Pharmaceuticals by 11.4% during the first quarter. ETF Managers Group LLC now owns 4,076 shares of the biopharmaceutical company’s stock valued at $144,000 after buying an additional 416 shares during the last quarter. Finally, Great West Life Assurance Co. Can bought a new stake in shares of Agios Pharmaceuticals during the fourth quarter valued at approximately $186,000. Institutional investors own 97.73% of the company’s stock.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next.

Featured Story: What is the Russell 2000 Index?

Analyst Recommendations for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.